Analysis of the efficacy of treatment with peginterferon α-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus

Liver International

Volumn 29, Issue 10, 2009, Pages 1485-1493

  Yu, Jian Wu ^a   Sun, Li Jie ^a   Zhao, Yong Hua ^a   Kang, Peng ^a   Gao, Jie ^a   Li, Shu Chen ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Coinfection; HBV; HCV; Hepatitis B virus; Hepatitis C virus; Sustained virological response; SVR

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS DNA; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANEMIA; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOTHYROIDISM; LEUKOCYTE COUNT; LIVER CIRRHOSIS; MALE; MIXED INFECTION; NEUTROPENIA; PROTHROMBIN TIME; RELAPSE; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VIRUS LOAD; VIRUS STRAIN;

ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL;

EID: 73349116572     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02080.x     Document Type: Article

References (21)

1. Crockett SD, Keeffe E.B. Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann Clin Microbiol Antimicrob 2005; 4: 13-25.
2. Liu Z, Hou J. Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection. Int J Med Sci 2006; 3: 57-62.
3. Tan A, Yeh SH, Liu CJ, et al. Viral hepatocarcinogenesis: from infection to cancer. Liver Int 2008; 28: 175-88.
4. Weltman MD, Brotodihardjo A, Crewe EB, et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995; 2: 39-45.
5. Zignego AL, Fontana R, Puliti S, et al. Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. J Med Virol 1997; 51: 313-8.
6. Sagnelli E, Coppola N, Scolastico C, et al. Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment. J Med Virol 2001; 65: 681-7.
7. Chuang WL, Dai CY, Chang WY, et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther 2005; 10: 125-33.
8. Potthoff A, Wedemeyer H, Boecher WO, et al. The HEPNET B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon Alfa-2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 2008; 49: 688-94.
9. Saitta C, Pontisso P, Brunetto MR, et al. Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy. Antivir ther 2006; 11: 931-4.
10. Yu JW, Wang GQ, Sun LJ, Li XG, Li S.C. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007; 22: 832-6.
11. APASL Hepatitis CWorking PartyMaCaughan GW, Omata M, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22: 615-33.
12. Lok AS, McMaho B.J. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
13. Chu CM, Yeh CT, Liaw Y.F. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J Clin Microbiol 1998; 36: 2084-6.
14. Dai CY, Yu ML, Chuang WL, et al. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2001; 16: 636-40.
15. Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 2006; 43: 100-7.
16. Fukuda R, Ishimura N, Hamamoto S, Moritani M, et al. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down regulation of type-I interferon receptor gene expression in the liver. J Med Virol 2001; 63: 220-7.
17. Liu CJ, Chen PJ, Lai MY, et al. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003; 37: 568-76.
18. Hung CH, Lee CM, Lu SN, et al. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol 2005; 20: 727-32.
19. Ferraro D, Bonura C, Giglio M, et al. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C. J Biol Regul Homeost Agents 2003; 17: 172-5.
20. Liu CJ, Chang WL, Lee CM, et al. Peginterferon Alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009; 136: 496-504.
21. Yalcin K, Degertekin H, Yildiz F, Kilinc N. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin. J Gastroenterol 2003; 38: 796-800..